| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.01B | +37.2% |
| Gross profit | ¥0.56B | — |
| Operating income | ¥0.13B | — |
| Net income | ¥0.11B | +17.3% |
| Gross margin | 55.2% | Net margin 10.6% |
| Revenue Q/Q | +2.3% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.45B | 44.8% |
| R&D | ¥0.02B | 2.2% |
| SG&A | ¥0.40B | 39.2% |
| Tax & other | ¥0.02B | 2.1% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
戎美股份 ・ 拓新药业 ・ 华润材料 ・ 深城交 ・ 争光股份 ・ 华兰股份 ・ 广立微 ・ 百诚医药 ・ 天益医疗 ・ 金埔园林 ・ 雅创电子 ・ 风光股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies